Skip to main content
Erschienen in: CME 9/2018

11.09.2018 | Gastroösophageale Refluxkrankheit | CME Fortbildung

Gastroösophagealer Reflux

Diagnostik und therapeutische Möglichkeiten

verfasst von: Priv.-Doz. Dr. J. Schedel, Prof. Dr. O. Pech

Erschienen in: CME | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die gastroösophageale Refluxerkrankung (GERD) ist ein häufiges Krankheitsbild mit klassischen und atypischen Symptomen. Bei suggestiver Symptomatologie und fehlenden Alarmsymptomen ist eine probatorische medikamentöse Therapie möglich, ansonsten umfasst die Diagnostik eine Ösophagogastroduodenoskopie (ÖGD), ggf. eine pH-Metrie/Impedanzmessung und eine Ösophagusmanometrie. Ziel ist es, dem Patienten eine zuverlässige Symptomlinderung zu ermöglichen. Protonenpumpeninhibitoren sind die medikamentösen Haupttherapeutika, aber auch operative Therapieoptionen existieren. Überwachungsalgorhythmen helfen, die möglichen Komplikationen der GERD im Sinne von Barrett-Metaplasie, Strikturen und Karzinom frühzeitig zu erkennen. Dysplastische Veränderungen in einer Barrett-Schleimhaut können je nach Ausmaß endoskopisch reseziert und abladiert oder chirurgisch entfernt werden.
Literatur
1.
Zurück zum Zitat Koop H, Fuchs KH, Labenz J et al. S2k-Leitlinie: Gastroösophageale Refluxerkrankung unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauens- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2014;52:1299–1346.CrossRefPubMed Koop H, Fuchs KH, Labenz J et al. S2k-Leitlinie: Gastroösophageale Refluxerkrankung unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauens- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 2014;52:1299–1346.CrossRefPubMed
2.
Zurück zum Zitat Vakil N, van Zanten SV, Kahrilas P et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900–1920.CrossRefPubMed Vakil N, van Zanten SV, Kahrilas P et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101(8):1900–1920.CrossRefPubMed
4.
Zurück zum Zitat Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308.CrossRefPubMed Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308.CrossRefPubMed
5.
Zurück zum Zitat Bytzer P, Jones R, Vakil N et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360CrossRefPubMed Bytzer P, Jones R, Vakil N et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2012;10:1360CrossRefPubMed
6.
Zurück zum Zitat Rex DK, Cummings OW, Shaw M et al. Screening for Barrett’s esophagus in colonoscopy patients with and without hearburn. Gastroenterology 2003;125(6):1670–1677.CrossRefPubMed Rex DK, Cummings OW, Shaw M et al. Screening for Barrett’s esophagus in colonoscopy patients with and without hearburn. Gastroenterology 2003;125(6):1670–1677.CrossRefPubMed
7.
Zurück zum Zitat Pehl C, Keller J, Meio R et al. Esophageal 24 hour-pH metry. Recommendations oft he German Society of Neurogastroenterology and Motility and the Study Group for Gastrointestinal Functional Disorders and Function Diagnostics of the Austrian Society of Gastroenterology aand Hepatology. Z Gastroenterol 2003;41:545–556.CrossRefPubMed Pehl C, Keller J, Meio R et al. Esophageal 24 hour-pH metry. Recommendations oft he German Society of Neurogastroenterology and Motility and the Study Group for Gastrointestinal Functional Disorders and Function Diagnostics of the Austrian Society of Gastroenterology aand Hepatology. Z Gastroenterol 2003;41:545–556.CrossRefPubMed
8.
Zurück zum Zitat Kessing BF, Smout AJ, Bredenoord AJ. Clinical Applikations of Esophageal Impedance Monitoring and High-Resolution Manometry. Curr Gastroenterol Rep 2012;14:197–205.CrossRefPubMedPubMedCentral Kessing BF, Smout AJ, Bredenoord AJ. Clinical Applikations of Esophageal Impedance Monitoring and High-Resolution Manometry. Curr Gastroenterol Rep 2012;14:197–205.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry. Valuable tools in clinical and investigational esophagology. Gastroenterology 2008;135:756–759.CrossRefPubMedPubMedCentral Kahrilas PJ, Sifrim D. High-resolution manometry and impedance-pH/manometry. Valuable tools in clinical and investigational esophagology. Gastroenterology 2008;135:756–759.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Ness-Jensen E, Hveem K, El-Serag H et al. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2016;14:175CrossRefPubMed Ness-Jensen E, Hveem K, El-Serag H et al. Lifestyle intervention in gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2016;14:175CrossRefPubMed
11.
Zurück zum Zitat Hempel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;145:199–211.CrossRef Hempel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005;145:199–211.CrossRef
12.
Zurück zum Zitat Ness-Jensen E, Lindam A, Lagergren J et al. Weight loss and reduction in gastroesophagel reflux. A prospectiv population-based cohort study: The HUNT study. Am J Gastroenterol 2013;108:376–382.CrossRefPubMed Ness-Jensen E, Lindam A, Lagergren J et al. Weight loss and reduction in gastroesophagel reflux. A prospectiv population-based cohort study: The HUNT study. Am J Gastroenterol 2013;108:376–382.CrossRefPubMed
13.
Zurück zum Zitat Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308–328.CrossRefPubMed Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308–328.CrossRefPubMed
14.
Zurück zum Zitat Fullard M, Kang JY, Neild P et al. Systematic review: does gastro-eosophageal reflux disease progress? Aliment Pharmacol Ther 2006;24:33–45.CrossRefPubMed Fullard M, Kang JY, Neild P et al. Systematic review: does gastro-eosophageal reflux disease progress? Aliment Pharmacol Ther 2006;24:33–45.CrossRefPubMed
15.
Zurück zum Zitat Van Pinxteren B, Sigterman KE, Bonis P et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews, 2010, Art. No: CD002095. (11):. DOI: 10.1002/14651858. CD002095.pub4. Van Pinxteren B, Sigterman KE, Bonis P et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews, 2010, Art. No: CD002095. (11):. DOI: 10.1002/14651858. CD002095.pub4.
16.
Zurück zum Zitat Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 200;118:S9. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 200;118:S9.
17.
Zurück zum Zitat Labenz J, Koop H. Gastro-oesophageal reflux disease — how to manage if PPI are not sufficiently effective, not tolerated or not wished? Dtsch Med Wochenschr 2017;142:356–366.CrossRefPubMed Labenz J, Koop H. Gastro-oesophageal reflux disease — how to manage if PPI are not sufficiently effective, not tolerated or not wished? Dtsch Med Wochenschr 2017;142:356–366.CrossRefPubMed
18.
Zurück zum Zitat Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed oesophagitis. A 6-month randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927–935.CrossRefPubMed Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed oesophagitis. A 6-month randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001;15:927–935.CrossRefPubMed
19.
Zurück zum Zitat Malfertheimer P, Lind T, Willich S et al. Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD): report from the ProGORD study. Gut 2005;54:746–751.CrossRef Malfertheimer P, Lind T, Willich S et al. Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD): report from the ProGORD study. Gut 2005;54:746–751.CrossRef
20.
Zurück zum Zitat Labenz J, Morgner-Miehlke A. An update on the available treatments for non-erosive reflux disease. Expert Opin Pharmacother 2006;7:47–56.CrossRefPubMed Labenz J, Morgner-Miehlke A. An update on the available treatments for non-erosive reflux disease. Expert Opin Pharmacother 2006;7:47–56.CrossRefPubMed
21.
Zurück zum Zitat Cremonini F, Ziogas DC, Chang HY et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010:32:29–42.CrossRefPubMedPubMedCentral Cremonini F, Ziogas DC, Chang HY et al. Meta-analysis: the effects of placebo treatment on gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2010:32:29–42.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:16–20.CrossRef Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003;98:16–20.CrossRef
23.
Zurück zum Zitat Viazis N, Keyoglou A, Kanellopoulos AH et al. Selective serotonin reuptake inhibitores for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012;107:1662–1667.CrossRefPubMed Viazis N, Keyoglou A, Kanellopoulos AH et al. Selective serotonin reuptake inhibitores for the treatment of hypersensitive esophagus: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2012;107:1662–1667.CrossRefPubMed
24.
Zurück zum Zitat Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308–328.CrossRefPubMed Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308–328.CrossRefPubMed
25.
Zurück zum Zitat Johnson DA, Benjamin SB, Vakil NB et al. Esomeprzole 20 mg once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastretrnol 2001;96:27–34.CrossRef Johnson DA, Benjamin SB, Vakil NB et al. Esomeprzole 20 mg once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastretrnol 2001;96:27–34.CrossRef
26.
Zurück zum Zitat Johnson DA, Katz PO, Levine D et al. Prevention of relapse of healed reflux esophagitis is related to the duration of intragastric pH>4. J Clin Gastroenterol 2010;44:475–478.PubMed Johnson DA, Katz PO, Levine D et al. Prevention of relapse of healed reflux esophagitis is related to the duration of intragastric pH>4. J Clin Gastroenterol 2010;44:475–478.PubMed
27.
Zurück zum Zitat Niklasson A, Lindstöm L, Simren M et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531–1537.CrossRefPubMed Niklasson A, Lindstöm L, Simren M et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010;105:1531–1537.CrossRefPubMed
28.
Zurück zum Zitat Yuan Y, Vinh B, Hunt RH. Non-healed rate of moderate-severe (LA classification grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): evidence of an unmet need. Gastroenterology 2009;137(Suppl 1):A–440. Yuan Y, Vinh B, Hunt RH. Non-healed rate of moderate-severe (LA classification grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): evidence of an unmet need. Gastroenterology 2009;137(Suppl 1):A–440.
29.
Zurück zum Zitat Reimer C, Lodrup AB, Smith G, et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther 2016; 43: 899–909.CrossRefPubMed Reimer C, Lodrup AB, Smith G, et al. Randomised clinical trial: alginate (Gaviscon Advance) vs. placebo as add-on therapy in reflux patients with inadequate response to a once daily proton pump inhibitor. Aliment Pharmacol Ther 2016; 43: 899–909.CrossRefPubMed
30.
Zurück zum Zitat Ali R, Egan L. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol 2007;21:793–806.CrossRefPubMed Ali R, Egan L. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol 2007;21:793–806.CrossRefPubMed
31.
Zurück zum Zitat Malfertheiner SF, Malfertheiner MV, Kropf S et al. A prospective longituinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol 2012:12:131.CrossRefPubMedPubMedCentral Malfertheiner SF, Malfertheiner MV, Kropf S et al. A prospective longituinal cohort study: evolution of GERD symptoms during the course of pregnancy. BMC Gastroenterol 2012:12:131.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Gill SK, O’Brien L, Einarson TR et al. The safety of proton pump inhibitors (PPSs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541–1545.CrossRefPubMed Gill SK, O’Brien L, Einarson TR et al. The safety of proton pump inhibitors (PPSs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009;104:1541–1545.CrossRefPubMed
33.
Zurück zum Zitat Fill S, Malfertheimer M, Costa SD et al. Handling of the gastroesophageal reflux disease (GERD) during pregnancy - a review. Z Geburtshilfe Neonatol 2007;211:215–223.CrossRefPubMed Fill S, Malfertheimer M, Costa SD et al. Handling of the gastroesophageal reflux disease (GERD) during pregnancy - a review. Z Geburtshilfe Neonatol 2007;211:215–223.CrossRefPubMed
34.
Zurück zum Zitat Jaspersen D, Kulig M, Labenz J et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003;17:1515–1520.CrossRefPubMed Jaspersen D, Kulig M, Labenz J et al. Prevalence of extra-oesophageal manifestations in gastro-oesophageal reflux disease: an analysis based on the ProGERD Study. Aliment Pharmacol Ther 2003;17:1515–1520.CrossRefPubMed
35.
Zurück zum Zitat Galmiche J-P, Hatlebakk J, Attwood S et al. Laparoscopic antirelulx sugery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. JAMA 2011;305:1969–1977.CrossRefPubMed Galmiche J-P, Hatlebakk J, Attwood S et al. Laparoscopic antirelulx sugery vs esomeprazole treatment for chronic GERD: The LOTUS randomized clinical trial. JAMA 2011;305:1969–1977.CrossRefPubMed
36.
Zurück zum Zitat Malfertheimer P, Nocon M, Vieth M et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care — the ProGERD study. Aliment Pharmacol Ther 2012;35:154–164.CrossRef Malfertheimer P, Nocon M, Vieth M et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care — the ProGERD study. Aliment Pharmacol Ther 2012;35:154–164.CrossRef
37.
Zurück zum Zitat Fein M, Bueter M, Thalheimer A et al. Ten year outcome of laparoscopic antireflux procedures. J Gastrointest Surg 2008;12:1893–1899.CrossRefPubMed Fein M, Bueter M, Thalheimer A et al. Ten year outcome of laparoscopic antireflux procedures. J Gastrointest Surg 2008;12:1893–1899.CrossRefPubMed
38.
Zurück zum Zitat Grant AM, Cotton SC, Boachie C and the REFLUX trial Group et al. Minimal Access Surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLXUX). Br Med J 2013;346:1908.CrossRef Grant AM, Cotton SC, Boachie C and the REFLUX trial Group et al. Minimal Access Surgery compared with medical management for gastro-oesophageal reflux disease: five year follow-up of a randomised controlled trial (REFLXUX). Br Med J 2013;346:1908.CrossRef
39.
Zurück zum Zitat Broeders JA, Rijnhart-de Jong HG, Braaaisma WA et al. Ten-year outcome of laparoscopic and conventional Nissen Fundoplication. Ann Surg 2009;250:698–705.CrossRefPubMed Broeders JA, Rijnhart-de Jong HG, Braaaisma WA et al. Ten-year outcome of laparoscopic and conventional Nissen Fundoplication. Ann Surg 2009;250:698–705.CrossRefPubMed
40.
Zurück zum Zitat Furnée EJB, Draiisma WA, Gooszen HG et al. Tailored or Routine Addition of an Antireflux Fundoplication in Laparoscopic Large Hiatal Hernia Repair: A Comparative Cohort Study. World J Surg 2011;35:78–84.CrossRefPubMed Furnée EJB, Draiisma WA, Gooszen HG et al. Tailored or Routine Addition of an Antireflux Fundoplication in Laparoscopic Large Hiatal Hernia Repair: A Comparative Cohort Study. World J Surg 2011;35:78–84.CrossRefPubMed
41.
Zurück zum Zitat Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C&M criteria. Gastroenterology 2006;131:1392–1399.CrossRefPubMed Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett’s esophagus: the Prague C&M criteria. Gastroenterology 2006;131:1392–1399.CrossRefPubMed
42.
Zurück zum Zitat Bennett C, Moayyedi P, Corley DA et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol 201;110:662 Bennett C, Moayyedi P, Corley DA et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am J Gastroenterol 201;110:662
43.
Zurück zum Zitat Anaparthy R, Gaddam S, Kanakadandi V et al. Association between length of Barrett’s esophagus and risk of high grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013;22:1542-… Anaparthy R, Gaddam S, Kanakadandi V et al. Association between length of Barrett’s esophagus and risk of high grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013;22:1542-…
44.
Zurück zum Zitat Koop H et al. S2k-Leitlinie: Gastroösophageale Refluxkrankheit. Z Gastroenterol 2014;52:1299–1346.CrossRefPubMed Koop H et al. S2k-Leitlinie: Gastroösophageale Refluxkrankheit. Z Gastroenterol 2014;52:1299–1346.CrossRefPubMed
45.
Zurück zum Zitat Mannath J, Subramanian V, Hawkey CJ e al. Narrow band imaging for characterization of high grade dysplasia and specialized interstinal metaplasia in Barrett’s esophagus: a meta-analysis. Endoscopy 2010;42:351–359.CrossRefPubMed Mannath J, Subramanian V, Hawkey CJ e al. Narrow band imaging for characterization of high grade dysplasia and specialized interstinal metaplasia in Barrett’s esophagus: a meta-analysis. Endoscopy 2010;42:351–359.CrossRefPubMed
46.
Zurück zum Zitat Sikkema M, de Jonge PJ, Steyerberg EW et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235.CrossRefPubMed Sikkema M, de Jonge PJ, Steyerberg EW et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235.CrossRefPubMed
47.
Zurück zum Zitat Singh S, Manickam P, Amin AV et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:897CrossRefPubMed Singh S, Manickam P, Amin AV et al. Incidence of esophageal adenocarcinoma in Barrett’s esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014;79:897CrossRefPubMed
48.
Zurück zum Zitat Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012;61:970–976.CrossRefPubMed Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut 2012;61:970–976.CrossRefPubMed
49.
Zurück zum Zitat Wani S, Rubenstein JH, Vieth M et al. Diagnosis and Management of low-grade dysplasia in Barrett’s esophagus: expert review from the Clinical Ppractice Updates Committee oft he American Gastroenterological Association. Gastroenterology 2016;151:822CrossRefPubMed Wani S, Rubenstein JH, Vieth M et al. Diagnosis and Management of low-grade dysplasia in Barrett’s esophagus: expert review from the Clinical Ppractice Updates Committee oft he American Gastroenterological Association. Gastroenterology 2016;151:822CrossRefPubMed
50.
Zurück zum Zitat Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dyplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105:1523–1530.CrossRefPubMed Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dyplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105:1523–1530.CrossRefPubMed
51.
Zurück zum Zitat Phoa KN, van Vilsteren FG, Weusten BL et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasisa: a randomized clinical trial. JAMA 2014;311:1209–1217.CrossRefPubMed Phoa KN, van Vilsteren FG, Weusten BL et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasisa: a randomized clinical trial. JAMA 2014;311:1209–1217.CrossRefPubMed
52.
Zurück zum Zitat Pech O, Bollschweiler E, Manner H et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers. Ann Surg 2011,254:67–72.CrossRefPubMed Pech O, Bollschweiler E, Manner H et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett’s esophagus at two high-volume centers. Ann Surg 2011,254:67–72.CrossRefPubMed
53.
Zurück zum Zitat Zemler B, May A, Ell C et al. Early Barrett’s carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion. Virchow Arch 2010;456:609–614.CrossRef Zemler B, May A, Ell C et al. Early Barrett’s carcinoma: the depth of infiltration of the tumour correlates with the degree of differentiation, the incidence of lymphatic vessel and venous invasion. Virchow Arch 2010;456:609–614.CrossRef
54.
Zurück zum Zitat Ell C, May A, Pech O et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc 2007;65:3–10.CrossRefPubMed Ell C, May A, Pech O et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc 2007;65:3–10.CrossRefPubMed
55.
Zurück zum Zitat May A, Gossner L, Pech O et al. Local endoscopic therapy for intrepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach Eur J Gastroenterol Hepatol 2002; 14:1085–1091.CrossRefPubMed May A, Gossner L, Pech O et al. Local endoscopic therapy for intrepithelial high-grade neoplasia and early adenocarcinoma in Barrett’s oesophagus: acute-phase and intermediate results of a new treatment approach Eur J Gastroenterol Hepatol 2002; 14:1085–1091.CrossRefPubMed
56.
Zurück zum Zitat Manner H, Pech O, Heldmann Y et al. Efficacy, safety and long-term results of endoscopic treatment for early-stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013;11:630–635.CrossRefPubMed Manner H, Pech O, Heldmann Y et al. Efficacy, safety and long-term results of endoscopic treatment for early-stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013;11:630–635.CrossRefPubMed
Metadaten
Titel
Gastroösophagealer Reflux
Diagnostik und therapeutische Möglichkeiten
verfasst von
Priv.-Doz. Dr. J. Schedel
Prof. Dr. O. Pech
Publikationsdatum
11.09.2018
Verlag
Springer Medizin
Erschienen in
CME / Ausgabe 9/2018
Print ISSN: 1614-371X
Elektronische ISSN: 1614-3744
DOI
https://doi.org/10.1007/s11298-018-6510-y

Weitere Artikel der Ausgabe 9/2018

CME 9/2018 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Neu im Fachgebiet Allgemeinmedizin

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.